|Bid||5.18 x 1400|
|Ask||5.54 x 1100|
|Day's Range||5.14 - 5.69|
|52 Week Range||2.54 - 11.57|
|Beta (5Y Monthly)||1.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 03, 2021 - Nov. 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.67|
DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix and Mike Andriole, Chief Financial and Business Officer of Chimerix, will participate in a pre-recorded fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference that will be made available on Monday, September
With me on today's call are president and chief executive officer, Mike Sherman; and chief financial and business officer, Mike Andriole. Allen Melemed, our chief medical officer; and Josh Allen, our chief technology officer of Imipridones, are here to participate in Q&A. Before we begin, I would like to remind you that statements made on today's call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties, and other factors.
Chimerix, Inc. ( NASDAQ:CMRX ) shareholders might be concerned after seeing the share price drop 17% in the last...